Русский | English    

 
 
One more opinion on biliary diseases           
  
  
Main         About author        
 
 
 
 

 
 

Gallbladder Dysfunction

Read this article in PDF format

The gallbladder dysfunction is a disorder of the gallbladder contraction which reveals as biliary pain (1). The cause of the gallbladder hypomotility can be an increased basal cystic duct resistance or cystic duct spasm, the muscle hypertrophy, or the chronic gallbladder diseases.

 

Diagnostic criteria of the gallbladder dysfunction

  1. Recurrent episodes of moderate or severe pain in the right hypochondrium or epigastrium which last for 20 minutes and more (pain is defined as moderate when it disrupts the patient’s daily activities, and as severe when medical consultation or medication is necessary).
  2. In addition, a patient may also experience one or more of the following symptoms:
    1. Nausea and vomiting
    2. Irradiation of pain in the right scapular region or in the right shoulder
    3. Pain occurs after a meal
    4. Pain occurs at night
  3. Impaired gallbladder emptying (the gallbladder ejection fraction is less than 40%).
  4. Absence of structural (morphological) changes explaining these symptoms.

 

Causes of the gallbladder evacuation dysfunction

  1. Pathology of the smooth muscle cells and epithelial cells in the gallbladder wall (high degree of COX-2 expression in the smooth muscle cells and epithelial cells of the gallbladder wall).
  2. Contractile dyscoordination of the gallbladder and cystic duct (high degree of COX-2 expression in the smooth muscle cells of the gallbladder and cystic duct).
  1. The cystic duct resistance increase (high degree of COX-2 expression in the smooth muscle cells of the cystic duct).

 

Mechanism of development of pathologic disorders

Decrease in the evacuation function of the gallbladder to less than 40% results in the decrease in the “active” and “passive” passage of the hepatic bile into the gallbladder and in the concentration of total bile acids in the gallbladder bile (fig. 11).

The decrease of the “active” and “passive” passage of the hepatic bile into the gallbladder results in the increase of the passage of the hepatic bile into duodenum and of the gallbladder-independent enterohepatic circulation of bile acids, biliary cholesterol and biliary bilirubin (fig. 12).

The increase of the gallbladder-independent enterohepatic circulation of bile acids causes increase in the concentration of bile acids in the hepatocytes and in the decrease of excretion function of the liver (i.e. formation of chronic “bland” intrahepatic cholestasis) (fig. 12).

The increase of the gallbladder-independent enterohepatic circulation of biliary cholesterol causes increase in the absorption of the biliary cholesterol in the small intestine, the biliary cholesterol entering the hepatocytes and the high secretion into hepatic bile (fig. 13). These two factors cause the formation of the “lithogenic” hepatic bile.

Decrease of the gallbladder-dependent output of biliary cholesterol and of the concentration of total bile acids in the gallbladder bile cause formation of the “lithogenic” gallbladder bile and precipitation of cholesterol monohydrate crystals in the gallbladder lumen on 10% of the patients with gallbladder dysfunction (fig. 14).

Precipitation of cholesterol monohydrate crystals on the epithelial cells of the gallbladder causes increase in COX-2 activity in the epithelial cells of the gallbladder mucosa and transformation of the gallbladder dysfunction into chronic acalculous cholecystitis without biliary sludge.

 

Pathogenetic treatment of patients with gallbladder dysfunction

Treatment of gallbladder dysfunction (gallbladder hypomotility with biliary pain) and for prophylactics of the chronic acalculous cholecystitis includes:

  1. Celecoxib - 100 mg, 2 times a day after meal for 5-7 days, after which
  2. Ursodeoxycholic acid - 750 mg, once a day (in the evening) for 2 weeks.

Celecoxib is a selective inhibitor of COX-2. Inhibiting COX-2 activity in the smooth muscle cells of the gallbladder wall and cystic duct results in the relief of the biliary pain within 3-5 days, restoration of the evacuation function of the gallbladder and the gallbladder-dependent output of biliary cholesterol, “active” passage of the hepatic bile into the gallbladder, and decrease in the gallbladder-independent enterohepatic circulation of bile acids, biliary cholesterol and biliary bilirubin.

Ursodeoxycholic acid, is a hydrophilic hepatoprotective bile acid. It helps in dissolving the cholesterol monohydrate crystals in the gallbladder, decrease in lithogenicity of the gallbladder and hepatic bile, disappearance of the chronic “bland” intrahepatic cholestasis (i.e. results in the restoration of the excretion function of the liver).   

Celecoxib is a selective inhibitor of COX-2. Inhibiting COX-2 activity in the smooth muscle cells of the biliary tract and the sphincter of Oddi it brings relief of the biliary pain within 3-5 days, restoration of the passage of the hepatic bile into the duodenum.

Celecoxib is a selective inhibitor of COX-2, inhibiting COX-2 activity in the epithelial cells of the biliary tract mucosa causes decrease in secretion of glycoprotein mucin into the biliary tract lumen, concentration of the glycoprotein biliary mucin in the hepatic bile and viscosity of hepatic bile, which prevents formation of biliary sludge and gallstones in the common hepatic duct and common bile duct. Low COX-2 activity in the epithelial cells and the smooth muscle cells of the biliary tract helps in lowering the risk of choledocholithiasis development.

Ursodeoxycholic acid (UDCA) is a hydrophilic hepatoprotective bile acid. It helps in dissolving the cholesterol monohydrate crystals in the biliary tract, decrease in lithogenicity of hepatic bile, disappearance of the chronic “bland” intrahepatic cholestasis (i.e. results in the restoration of the accumulation and excretion functions of liver), and in some patients helps in dissolving the biliary sludge in the biliary tract.

Ursodeoxycholic acid (UDCA) is a hydrophilic hepatoprotective bile acid, decreasing aggressive properties of bile, prevents development of chronic atrophic antral gastritis (duodenogastric reflux and bile reflux gastritis) and duodeno-gastroesophageal reflux (incompetence of Oddi's sphincter), chronic biliary pancreatitis (biliopancreatic reflux) or chronic spastic aseptic pancreatitis (pancreatic type III of sphincter of Oddi dysfunction).

Celecoxib and Ursodeoxycholic acid (UDCA), pathogenetically blocking main mechanisms of gallstone formation, help in prophylactics of gallstone formation in the biliary tract, and lower the risk of development of choledocholithiasis and chronic biliary pancreatitis (1-66).

Effectiveness is 95%.
Remission period is 18-24 months.

 

Attention!!! Information for patients:

Before using this scheme of treatment please check the contraindications (below) and side effects of using pharmacological preparations of Celecoxib and Ursodeoxycholic acid, and obtain your doctor’s permission.

Contraindications for Celecoxib:

  • allergic reactions (nettle-rash, bronchial spasm) to acetylsalicylic acid or other NSAIDs (in anamnesis);
  • 3rd trimester of pregnancy;
  • high sensitivity to sulphonamides;
  • high sensitivity to any component of the preparation.

Contraindications for Ursodeoxycholic acid:

  • high sensitivity to the preparation;
  • acute inflammatory diseases of the gallbladder and the bile ducts;
  • ulcerative colitis;
  • Crone’s disease.

This web page does not bear any legal responsibility for the use of the proposed treatment schemes without consulting your doctor.

 

References:

  1. Extrahepatic biliary system diseases: the gallbladder dysfunction and states after cholecystectomy. International Bulletin: gastroenterology. 2001; 6: 1-4.

 

References (Celecoxib and UDCA):

  1. Chen XW, Cai JT. The impact of selective cycloxygenase-2 inhibitor celexibo on the formation of cholesterol gallstone. Zhonghua Nei Ke Za Zhi. 2003; 42(11): 797-9.
  2. Guarino MP, Carotti S, Sarzano M, Alloni R, Vanni M, Grosso M, Sironi G, Maffettone PL, Cicala M. Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. Neurogastroenterol Motil. 2005; 17(5): 680-6.
  3. Pazzi P, Petroni ML, Prandini N, Adam JA, Gullini S, Northfield TC, Jazrawi RP. Postprandial refilling and turnover: specific gallbladder motor function defects in patients with gallstone recurrence. Eur J Gastroenterol Hepatol. 2000; 12(7): 787-94.
  4. Ikegami T, Matsuzaki Y, Fukushima S, Shoda J, Olivier JL, Bouscarel B, Tanaka N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology. 2005; 41(4): 896-905.
  5. Shoda J, Ueda T, Kawamoto T, Todoroki T, Asano T, Sugimoto Y, Ichikawa A, Maruyama T, Nimura Y, Tanaka N. Prostaglandin E receptors in bile ducts of hepatolithiasis patients and the pathobiological significance for cholangitis. Clin Gastroenterol Hepatol. 2003; 1(4): 285-96.
  6. Shoda J, Kano M, Asano T, Irimura T, Ueda T, Iwasaki R, Furukawa M, Kamiya J, Nimura Y, Todoroki T, Matsuzaki Y, Tanaka N. Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis. Hepatology. 1999; 29(4): 1026-36.
  7. Tomida S, Abei M, Yamaguchi T, Matsuzaki Y, Shoda J, Tanaka N, Osuga T. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology. 1999; 30(1): 6-13.
  8. Kano M, Shoda J, Irimura T, Ueda T, Iwasaki R, Urasaki T, Kawauchi Y, Asano T, Matsuzaki Y, Tanaka N. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology. 1998; 28(2): 302-13.
  9. Shoda J, Ueda T, Ikegami T, Matsuzaki Y, Satoh S, Kano M, Matsuura K, Tanaka N. Increased biliary group II phospholipase A2 and altered gallbladder bile in patients with multiple cholesterol stones. Gastroenterology. 1997; 112(6): 2036-47.
  10. Carotti S, Guarino MP, Cicala M, Perrone G, Alloni R, Segreto F, Rabitti C, Morini S. Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterol Motil. 2010.
  11. Guarino MP, Carotti S, Morini S, Perrone G, Behar J, Altomare A, Alloni R, Caviglia R, Emerenziani S, Rabitti C, Cicala M. Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut. 2008; 57(12): 1740-1.
  12. Jüngst C, Sreejayan N, Zündt B, Müller I, Spelsberg FW, Hüttl TP, Kullak-Ublick GA, del Pozo R, Jüngst D, von Ritter C. Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. Eur J Clin Invest. 2008; 38(9): 634-9.
  13. Spier BJ, Pfau PR, Lorenze KR, Knechtle SJ, Said A. Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. Liver Transpl. 2008; 14(10): 1461-5.
  14. Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut. 2007; 56(6): 815-20.
  15. Mas MR, Comert B, Mas N, Yamanel L, Ozotuk H, Tasci I, Jazrawi RP. Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. World J Gastroenterol. 2007; 13(32): 4336-9.
  16. Jüngst C, Sreejayan N, Eder MI, von Stillfried N, Zündt B, Spelsberg FW, Kullak-Ublick GA, Jüngst D, von Ritter C. Lipid peroxidation and mucin secretagogue activity in bile of gallstone patients. Eur J Clin Invest. 2007; 37(9): 731-6.
  17. Itoh S, Kono M, Akimoto T. Psoriasis treated with ursodeoxycholic acid: three case reports. Clin Exp Dermatol. 2007; 32(4): 398-400.
  18. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(6): 318-28.
  19. Colecchia A, Mazzella G, Sandri L, Azzaroli F, Magliuolo M, Simoni P, Bacchi-Reggiani ML, Roda E, Festi D. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J Gastroenterol. 2006; 12(33): 5336-43.
  20. Pemberton PW, Aboutwerat A, Smith A, Warnes TW. Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation. Redox Rep. 2006; 11(3): 117-23.
  21. Jeong HJ, Kim CG. Pretreatment with ursodeoxycholic acid (UDCA) as a novel pharmacological intervention in hepatobiliary scintigraphy. Yonsei Med J. 2005; 46(3): 394-8.
  22. Fischer S, Müller I, Zündt BZ, Jüngst C, Meyer G, Jüngst D. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol. 2004; 16(3): 305-11.
  23. Sauter GH, Thiessen K, Parhofer KG, Jüngst C, Fischer S, Jüngst D. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects. Digestion. 2004; 70(2): 79-83.
  24. Xiao ZL, Biancani P, Carey MC, Behar J. Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis. Hepatology. 2003; 37(6): 1442-50.
  25. Tazuma S, Nishioka T, Ochi H, Hyogo H, Sunami Y, Nakai K, Tsuboi K, Asamoto Y, Sakomoto M, Numata Y, Kanno K, Yamaguchi A, Kobuke T, Komichi D, Nonaka Y, Chayama K. Impaired gallbladder mucosal function in aged gallstone patients suppresses gallstone recurrence after successful extracorporeal shockwave lithotripsy. J Gastroenterol Hepatol. 2003; 18(2): 157-61.
  26. Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology. 2002; 49(44): 497-500.
  27. Xiao ZL, Rho AK, Biancani P, Behar J. Effects of bile acids on the muscle functions of guinea pig gallbladder. Am J Physiol Gastrointest Liver Physiol. 2002; 283(1): G87-94.
  28. Kano M, Shoda J, Satoh S, Kobayashi M, Matsuzaki Y, Abei M, Tanaka N. Increased expression of gallbladder cholecystokinin: a receptor in prairie dogs fed a high-cholesterol diet and its dissociation with decreased contractility in response to cholecystokinin. J Lab Clin Med. 2002; 139(5): 285-94.
  29. Wang DQ, Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002; 43(11): 1960-8.
  30. Lukivskaya OY, Maskevich AA, Buko VU. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver. Alcohol. 2001; 25(2): 99-105.
  31. Bomzon A, Ljubuncic P. Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids. Dig Dis Sci. 2001; 46(9): 2017-24.
  32. Sunami Y, Tazuma S, Kajiyama G. Gallbladder dysfunction enhances physical density but not biochemical metastability of biliary vesicles. Dig Dis Sci. 2000; 45(12): 2382-91.
  33. Ljubuncic P, Said O, Ehrlich Y, Meddings JB, Shaffer EA, Bomzon A. On the in vitro vasoactivity of bile acids. Br J Pharmacol. 2000; 131(3): 387-98.
  34. Nishioka T, Tazuma S, Yamashita G, Kajiyama G. Partial replacement of bile salts causes marked changes of cholesterol crystallization in supersaturated model bile systems. Biochem J. 1999; 340 ( Pt 2): 445-51.
  35. Sinisalo J, Vanhanen H, Pajunen P, Vapaatalo H, Nieminen MS. Ursodeoxycholic acid and endothelial-dependent, nitric oxide-independent vasodilatation of forearm resistance arteries in patients with coronary heart disease. Br J Clin Pharmacol. 1999; 47(6): 661-5.
  36. van de Heijning BJ, van de Meeberg PC, Portincasa P, Doornewaard H, Hoebers FJ, van Erpecum KJ, Vanberge-Henegouwen GP. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci. 1999; 44(1): 190-6.
  37. Mendez-Sanchez N, Brink MA, Paigen B, Carey MC. Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology. 1998; 115(3): 722-32.
  38. Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, Di Sario A, Baiocchi L, Jezequel AM. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology. 1997; 26(1): 9-21.
  39. Ohtake M, Sandoh N, Sakaguchi T, Tsukada K, Hatakeyama K. Enhancement of portal blood flow by ursodesoxycholic acid in partially hepatectomized rats. Surg Today. 1996; 26(2): 142-4.
  40. Fahey DA, Carey MC, Donovan JM. Bile acid/phosphatidylcholine interactions in mixed monomolecular layers: differences in condensation effects but not interfacial orientation between hydrophobic and hydrophilic bile acid species. Biochemistry. 1995; 34(34): 10886-97.
  41. Bouscarel B, Ceryak S, Robins SJ, Fromm H. Studies on the mechanism of the ursodeoxycholic acid-induced increase in hepatic low-density lipoprotein binding. Lipids. 1995; 30(7): 607-17.
  42. Bomzon A, Ljubuncic P. Bile acids as endogenous vasodilators? Biochem Pharmacol. 1995; 49(5): 581-9.
  43. Jazrawi RP, Pazzi P, Petroni ML, Prandini N, Paul C, Adam JA, Gullini S, Northfield TC. Postprandial gallbladder motor function: refilling and turnover of bile in health and in cholelithiasis. Gastroenterology. 1995; 109(2): 582-91.
  44. Pak JM, Adeagbo AS, Triggle CR, Shaffer EA, Lee SS. Mechanism of bile salt vasoactivity: dependence on calcium channels in vascular smooth muscle. Br J Pharmacol. 1994; 112(4): 1209-15.
  45. Sasaki H, Tazuma S, Kajiyama G. Effects of 16,16-dimethyl prostaglandin E2 on biliary mucous glycoprotein and gallstone formation in guinea pigs. Scand J Gastroenterol. 1993; 28(6): 495-9.
  46. Mizuno S, Tazuma S, Kajiyama G. Stabilization of biliary lipid particles by ursodeoxycholic acid. Prolonged nucleation time in human gallbladder bile. Dig Dis Sci. 1993; 38(4): 684-93.
  47. Pak JM, Lee SS. Vasoactive effects of bile salts in cirrhotic rats: in vivo and in vitro studies. Hepatology. 1993; 18(5): 1175-81.
  48. Das JB, Cosentino CM, Levy MF, Ansari GG, Raffensperger JG. Early hepatobiliary dysfunction during total parenteral nutrition: an experimental study. J Pediatr Surg. 1993; 28(1): 14-8.
  49. Fromm H, Malavolti M. Bile acid dissolution therapy of gallbladder stones. Baillieres Clin Gastroenterol. 1992; 6(4): 689-95.
  50. Tazuma S, Sasaki H, Mizuno S, Sagawa H, Hashiba S, Horiuchi I, Kajiyama G. Effect of ursodeoxycholic acid administration on nucleation time in human gallbladder bile. Gastroenterology. 1989; 97(1): 173-8.
   

 

Active and passive passge of hepatic bile, gallbladder dysfunction
Fig. 11


Enterohepatic circulation of bile acids, gallbladder dysfunction
Fig. 12


Cholesterol metabolism, gallbladder dysfunction
Fig. 13


Cholesterol and bile acids metabolism, gallbladder dysfunction
Fig. 14



 
 
 
      ©   Я.Л. Тюрюмин,   2010